生物仿制药批准的全球监管格局不断变化:当前的挑战和趋同的机会
Elif Car1, Liese Barbier1, Isabelle Huys1
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Expert opinion on biological therapy
|May 26, 2025
概括
生物仿制药提高了生物的获取和可负担性. 协调全球生物仿制药批准的监管要求可以加速开发,并改善患者获得高质量,安全和成本效益的治疗.
科学领域:
- 药物经济学 药物经济学
- 监管科学 监管科学
- 生物制药开发 生物制药开发
背景情况:
- 生物仿制药增加了竞争,改善了获得生物制药的机会,而不会损害安全性或有效性.
- 对生物类似药物的独立,司法管辖区特定的监管要求使全球发展复杂化,成本增加.
- 分析科学的进步和生物类药物批准的广泛经验需要对监管标准进行重新评估.
研究的目的:
- 确定证明生物相似性的挑战.
- 提供全球生物类药物监管要求的全面概述.
- 探索监管趋同和协调的机会.
主要方法:
- 进行了结构化的文献综述.
- 搜索的数据库包括PubMed,Embase和科学网.
- 在选相关性后,包括了61篇文章.
主要成果:
- 欧洲药物管理局和美国食品和药物管理局等当局的监管准则是强有力的,但美国和欧盟标准之间的进一步协调是可行的.
- 新兴市场的生物相似监管要求可能与科学进步或累积的临床经验不一致.
- 生物相似药物指南的全球协调是可能的,利用现有的发展和监管经验.
结论:
- 协调生物类似药物监管要求可以加速开发和批准过程.
- 全球协调可以提高患者获得安全,有效和负担得起的生物药物的机会.
- 修订监管标准反映了科学进步和现实世界生物类似药物的经验.
关键词:
生物制剂 生物制剂 生物制剂生物相似性 生物相似性生物类似药的生物类似药.药物的批准 药物的批准药物开发是药物的发展.这些指导方针是指导方针.监管 监管 监管 监管 监管 监管监管评估 监管评估 监管评估 监管评估更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
相关概念视频
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Drug Control Governance: Regulatory Bodies and Their Impact
146
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
146
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
